EQS-News: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
- AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
The issuer is solely responsible for the content of this announcement. - “We are excited that our partner MSD received FDA approval for PREVYMIS® (letermovir) for the prophylaxis of CMV infection in kidney transplanted patients.
- Since 2017, the drug has already protected thousands of allogeneic stem cell transplanted patients from CMV disease.
- With this label expansion, CMV-seropositive kidney transplant patients now have a novel, safe and effective treatment option,” said Larry Edwards, CEO of AiCuris Anti-infective Cures AG.